A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Of nearly 1 million members receiving 2 doses of BNT162b2 in January–February 2021, infection rates (based on polymerase chain reaction results) were compared between those who received a third dose with those who did not during August–October 2021 (maximum, 70 days). Crude VE was 92.9% (95% confidence interval [CI], 92.6%–93.2%) and adjusted VE was 89.1% (95% CI, 87.5%–90.5%). We conclude that the third dose provides added protection against SARS-CoV-2 infection for those vaccinated 6 months ago.

中文翻译：

---

第三剂 BNT162b2 mRNA 疫苗的有效性


以色列一家大型健康维护组织进行了一项回顾性队列研究，以确定第三剂 BNT162b2 疫苗针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 感染的疫苗有效性 (VE)。在 2021 年 1 月至 2 月期间，有近 100 万会员接受了 2 剂 BNT162b2，对 2021 年 8 月至 10 月期间接受第三剂 BNT162b2 的感染率（基于聚合酶链反应结果）进行了比较（最长 70 天） ）。粗 VE 为 92.9%（95% 置信区间 [CI]，92.6%–93.2%），调整后 VE 为 89.1%（95% CI，87.5%–90.5%）。我们的结论是，第三剂疫苗为 6 个月前接种疫苗的人提供了针对 SARS-CoV-2 感染的额外保护。